-
New Phase III Trial Explores Adding Targeted Immunotherapy to Hodgkin Lymphoma Treatment
A phase III clinical trial is now comparing standard chemotherapy for early-stage Hodgkin lymphoma to a regimen that adds two targeted therapies, brentuximab vedotin and nivolumab, in hopes of improving survival and reducing side effects.
-
New Trial Aims to Sharpen MRSA Treatment by Comparing Two Leading Therapies
A new randomized trial will directly compare daptomycin, a cyclic lipopeptide antibiotic, against vancomycin for treating MRSA bloodstream infections, aiming to guide better treatment choices.
-
Lilly’s Triple-Agonist Retatrutide Shows Powerful Weight Loss in Pivotal Phase 3 Trial
Eli Lilly’s investigational triple agonist retatrutide produced substantial weight loss in a pivotal Phase 3 obesity trial, marking another milestone for next-generation metabolic peptides.
-
FDA Advisory Panel Votes to Ease Restrictions on Four Peptides
An FDA advisory panel has voted in favor of loosening restrictions on four peptide compounds, a move that could expand access and support further research and development.
-
FDA Advisory Panel Backs Expanded Access to Certain Peptide Therapies
An FDA advisory panel has voiced support for broadening the availability of select peptide-based treatments, a signal that could pave the way for wider patient access. The recommendation reflects growing regulatory confidence in peptide therapeutics.
-
FDA Advisory Panel Signals Support for Compounded Peptide Access
An FDA advisory panel has reportedly recommended allowing continued compounding of certain unapproved peptides, a move that could preserve patient access to these therapies while formal approval pathways progress.
-
Retatrutide Shows Remarkable Weight-Loss Results, Rivaling Surgical Outcomes
Early clinical data on retatrutide, a new investigational peptide, show participants losing up to 30% of body weight—results comparable to bariatric surgery. Experts see this as a major step forward in non-surgical obesity treatment.
-
Understanding C-Peptide: A Key Biomarker Advancing Type 1 Diabetes Research
C-peptide, a byproduct of insulin production, is helping researchers better measure remaining beta-cell function in people with type 1 diabetes—supporting progress toward new therapies.
-
FDA Advisory Panel Recommends Easing Restrictions on Popular Peptides
An FDA advisory panel has voted to recommend loosening current restrictions on certain peptide compounds, a move that could expand access for patients and practitioners.
-
FDA Advisory Committee Backs Compounding for Six Popular Peptides
An FDA advisory panel has determined that six widely used peptides meet the criteria for pharmacy compounding, a step that could preserve patient access to these therapies through compounding pharmacies.